UNSPSC 51282502: Cefadroxil

This classification denotes a cephalosporin antibiotic with the molecular formula C16H17N3O5S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 280111G160, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6r-(6-alpha,7-beta(r*)))- but generally known as cefadroxil, which bears US NIH Compound Identifier 2610. Cefadroxil most often comes in base, hydrate, and hemihydrate forms.

UNSPSC 51282502 Cefadroxil is a Commodity code that nominally denotes a specific antibiotic product, but recent state and local procurement activity under this code shows minimal alignment with the code's narrow pharmaceutical scope. The most active solicitations posted against this code are for broad medical and first aid supplies (including respiratory equipment, cardiac monitoring devices, and emergency response consumables), direct-to-manufacturer pharmacy benefit programs, and multi-state generic pharmaceutical contracting—work that spans far beyond a single antibiotic formulation. State and local buyers using this code include county health departments (Seminole County, Florida), municipal fire departments (City of Tampa), state health agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and participating jurisdictions). The code shows low frequency of actual activity, and the opportunities posted against it suggest either catalog misclassification by issuing bodies or a mismatch between the code's intended scope and its real-world application in state and local procurement.

Recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems (due July 26, 2023); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000 and a bid deadline of March 13, 2026; the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (due April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products across multiple states, with proposals due March 26, 2026. Activity is concentrated in Florida and Texas, with multi-state reach through cooperative purchasing vehicles. Vendors pursuing work tagged to this code should verify actual commodity scope before bid preparation, as the code's nominal definition does not reliably reflect the scope of work being solicited.